Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1747-1752

  Hainsworth, John D ^a   Spigel, David R ^a   Farley, Cindy ^a   Thompson, Dana S ^a   Shipley, Dianna L ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EDEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTICEMIA; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248995210     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3047     Document Type: Article

References (25)

1. Eagan R, Therneau TM, Rubin J, et al: Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 10:82-85, 1987
2. Goldberg R, Smith FP, Ueno W, et al: 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol 4:395-399, 1986
3. Greco F, Burris HA, Erland JA, et al: Carcinoma of unknown primary site: Long-term follow-up after treatment with paclitaxel, carboplatin, and etoposide. Cancer 89:2655-2660, 2000
4. Greco FA, Gray J, Burris HA III, et al: Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 7:203-212, 2001
5. Abbruzzese JL, Abbruzzese MC, Hess KR, et al: Unknown primary carcinoma: Natural history and prognostic factors in 657 patients. J Clin Oncol 12:1272-1280, 1994
6. Hess KR, Abbruzzese MC, Lenzi R, et al: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403-3410, 1999
7. Hainsworth JD, Johnson DH, Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10:912-922, 1992
8. Culine S, Kramer A, Saghatchian M, et al: Development and validation of a prognostic model to predict the length of survival in patients with carcinoma of an unknown primary site. J Clin Oncol 20:4679-4683, 2002
9. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al: Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinoma of unknown primary site. Cancer 107:2698-2705, 2006
10. Hainsworth JD, Burris HA, Calvert SW, et al: Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Res Network. Cancer Invest 19:335-339, 2001
11. Hainsworth JD, Spigel DR, Raefsky EL, et al: Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: A Minnie Pearl Cancer Res Network phase II trial. Cancer 104:1992-1997, 2005
12. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997
13. Yang-JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
14. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
15. Sandler AB, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
16. Miller KD, Wang M, Gralow J, et al: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group. Breast Cancer Res Treat 94:S6, 2005 (abstr 3)
17. Shepherd FA, Pereira JR, Ciuleunu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-132, 2005
18. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 23:1s, 2005 (suppl; abstr 1)
19. Riedel F, Gotte K, Li M, et al: EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol 21:11-16, 2002
20. Ciardiello F, Caputo R, Branco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465, 2001
21. Vilona-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
22. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555, 2005
23. Hainsworth JD, Sosman JA, Spigel DR, et al: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896, 2005
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958